Research
Hormonal
Intentional weight loss via GLP-1 receptor agonists (liraglutide, semaglutide) and SGLT2 inhibitors (empagliflozin) reduces cardiovascular events and mortality in type 2 diabetes patients, contradicting the 'obesity paradox' which suggests higher BMI is protective.
If you have Type 2 Diabetes, medications like GLP-1 agonists (e.g., liraglutide, semaglutide) or SGLT2 inhibitors (e.g., empagliflozin) are proven to help your heart and reduce weight. Do not rely on the 'obesity paradox' to justify carrying excess weight; these drugs actively reduce cardiovascular risk and mortality.
StrongSupportsHIGH confidence
Recent cardiovascular (CV) outcome trials of treatments for type 2 diabetes mellitus (T2DM) including Glucagon like peptide -1 (GLP-1) receptor agonists and Sodium-glucose co-transporter-2 (SGLT2) inhibitor have shown beneficial effects on both CV outcomes and body weight.
Why this rating
Based on large-scale, randomized, double-blind Cardiovascular Outcome Trials (CVOTs) like LEADER, SUSTAIN-6, and EMPA-REG.
Source
Can we reconcile ‘the obesity paradox’ with recent cardiovascular outcome trials in diabetes?
Andrew C. Jamieson et al. · Clinical Obesity · 2017
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →